CRO · Built to order
CRO market and partner assessment: recovery, consolidation and partner fit
Where the CRO recovery is real, which partners fit which programmes, and how integrated data platforms are changing the choice.
What you receive
- A written report that answers the questions agreed at scoping, with a clear verdict on each
- The read from the leaders running these businesses, gathered through our search work and attributed by role
- A data workbook with the underlying tables, so your team can filter, check and reuse the work
- A source register with the source and date behind each key fact
What can be in scope
- Market reading by segment: clinical delivery, laboratory and early phase
- Consolidation and site changes among candidate partners
- Partner fit for the programme: modality, phase, geography and data delivery
- Key-person exposure on named studies
- Diligence questions for partner selection
The CRO recovery is uneven. Clinical delivery and the specialist laboratory and early-phase layer behave differently, and consolidation in the lab layer can remove named, regulated individuals that a study depends on.
This assessment reads the market by segment and assesses candidate partners against a programme's needs, including complex modalities and integrated data delivery.
Who commissions it
- Sponsors selecting or reviewing CRO partners
- Investors in CROs and CRO-dependent companies
- CRO strategy and business development teams
- Corporate development teams assessing CRO acquisitions
The questions it answers
- Which CRO segments are recovering, and which are consolidating sites and functions?
- Which candidate partners fit the programme's modality, phase and geography?
- Who are the named study directors and bioanalytical leads on a study, and how likely are they to stay?
- Which CROs can deliver integrated data across bioanalytical, clinical and real-world evidence?
- What should a sponsor ask a CRO before signing?
What you are buying access to
A proprietary intelligence base
Producers, facilities, pipelines, transactions, compensation and dated market signals across radiopharma, ADC, cell and gene therapy, CDMO and CRO, built and maintained by ProGen.
Access to the people who run it
Our executive search work puts us in conversation with the leaders of these businesses every week. Their read on the market goes into your answer.
Built around your decision
Scoped to the call in front of you: an investment, a partner, a supplier or a market. Every key fact sourced and dated.
How it works
Tell us your question
Choose an analysis below or describe your own. The more specific the decision, the sharper the scope.
Scope and quotation within one business day
We reply with the questions we will answer, what is in and out of scope, the timeline and a fixed quotation.
Your answer, built to stand up
A written report with a clear verdict, the read from the leaders in the space, a data workbook and a source register.
Request this analysis
Tell us the decision and the questions behind it. Within one business day you have the scope, the timeline and a fixed quotation.
